Comparative Efficacy and Safety of the Bevacizumab Biosimilar MIL60 versus Bevacizumab Reference in Patients with Advanced or Recurrent Nonsquamous NSCLC

2021 Year in Review - Biosimilars —December 30, 2021



The results of a randomized, double-blind phase 3 study established the equivalence of bevacizumab reference to its biosimilar MIL60 in terms of clinical efficacy, safety, population pharmacokinetics, and immunogenicity in patients with nonsquamous NSCLC.

The results of a randomized phase 3 study that compared the efficacy, safety, population pharmacokinetics (PK), and immunogenicity of MIL60, a bevacizumab biosimilar, with bevacizumab reference product in patients with advanced or recurrent nonsquamous non–small-cell lung cancer (NSCLC) were reported at the 2021 European Society for Medical Oncology Annual Meeting.

This randomized, double-blind phase 3 study (NCT03196986) randomized patients with untreated advanced/recurrent NSCLC. Between August 23, 2017, and August 1, 2019, patients received MIL60 or bevacizumab reference (15 mg/kg on day 1 of each cycle every 3 weeks) in combination with paclitaxel/carboplatin, followed by MIL60 single-agent (7.5 mg/kg) maintenance treatment until disease progression or intolerable toxicity. The primary end point was the objective response rate (ORR) at week 12.

The study included a total of 517 patients; of these, 257 received MIL60 and 260 received bevacizumab reference. At week 12, the ORRs were similar in the MIL60 and bevacizumab reference groups (48.6% vs 43.1%). The equivalence of the 2 groups was established based on an ORR ratio of 1.14 (90% confidence interval, 0.97-1.33), which fell within the prespecified equivalence boundaries (0.75-1/0.75). Updated analysis (from October 31, 2020) reported comparable median duration of response (5.7 months vs 5.6 months; hazard ratio [HR], 0.92; P = .6409), median progression-free survival (7.2 vs 8.1 months; HR, 1.01; P = .9606), and overall survival (19.3 vs 16.3 months; HR, 0.81; P = .0755). For PK parameters, there was no significant difference in the exposure of MIL60 and bevacizumab reference.

Overall, the safety and tolerability profiles of MIL60 and bevacizumab reference were comparable in terms of grade ≥3 treatment-emergent adverse events (70.3% vs 72.6%) and serious adverse events (28.1% vs 28.6%). In both the MIL60 and bevacizumab groups, antidrug antibodies were undetectable.

Based on these results, it was concluded that MIL60 and bevacizumab reference are equivalent in clinical efficacy, safety, population PK, and immunogenicity in patients with nonsquamous NSCLC.

Source: Wang J, Wang R, Dong X, et al. Efficacy and safety of MIL60, a bevacizumab biosimilar, in combination with paclitaxel/carboplatin in patients with advanced or recurrent non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter phase III study. Ann Oncol. 2021;32(suppl_5):S1023.

Related Articles
Real-World Overall Response Rate and Other Outcomes Related to Originator and Biosimilar Rituximab in Patients with CLL or NHL in the United Kingdom
2021 Year in Review - Biosimilars
The results of a noninterventional, retrospective study showed that rituximab originator and the rituximab-abbs biosimilars yielded comparable efficacy and tolerability in the first-line treatment of patients with CLL and NHL, with rituximab-abbs use resulting in cost-savings.
Cost-Effectiveness of Subcutaneous Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for the Treatment of High-Risk, HER2-Positive Early Breast Cancer
2021 Year in Review - Biosimilars
Findings from modeling studies support adjuvant continuation of pertuzumab plus trastuzumab for patients achieving pathologic complete response among patients with high-risk, HER2-positive early breast cancer.
Same-Day Pegfilgrastim or PFG-cbqv Prophylaxis of Chemotherapy-Induced Neutropenia in Bendamustine plus Rituximab and CHOP±R Regimens in Patients with Lymphoma and CLL
2021 Year in Review - Biosimilars
Real-world outcomes from a retrospective, single-center study suggested that pegfilgrastim or its biosimilar pegfilgrastim-cbqv does not increase febrile neutropenia or delayed engraftment risk in patients with lymphoma and CLL and may be safe to use after administration of chemotherapy.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State